- Short communication
- Open Access
MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations
© San José-Enériz et al; licensee BioMed Central Ltd. 2009
- Received: 4 June 2009
- Accepted: 1 September 2009
- Published: 1 September 2009
The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients. The existence of second generation TK inhibitors, which are effective in patients with IM resistance, makes identification of predictors of resistance to IM an important goal in CML. In this study, we have identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML.
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Imatinib Mesylate
- Chronic Myeloid Leukemia Patient
The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML) . Treatment with IM induces a complete hematological and cytogenetic response in more than 90 and 80% of newly diagnosed patients with chronic phase CML respectively,  which has established IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients . Different mechanisms of resistance have been described, including the presence of point mutations in the tyrosine kinase domain of BCR-ABL1, amplification and overexpression of BCR-ABL1, overexpression of efflux transporters (such as ABCB1, also known as MDR1 or p-glycoprotein, and ABCG2) and underexpression of uptake transporters (such as SLC22A1, also known as hOCT1) . However, it is currently impossible to predict whether a patient will develop resistance to IM. The existence of second generation TK inhibitors, which are effective in patients with IM resistance, makes identification of predictors of resistance to IM an important goal in CML.
MicroRNAs (miRNAs) are non-coding, single-stranded RNAs of 21-25 nucleotides that have recently been implicated in the regulation of a number of biological processes such as development, differentiation, apoptosis, proliferation and hematopoiesis. They regulate gene expression by promoting degradation of the mRNA or repressing its translation . In addition, miRNAs have been implicated in the development of human cancers, either as tumor suppressors or as oncogenes. Aberrant miRNA expression has recently been described for a variety of solid tumors (lung, breast or colorectal cancer among others) and hematological malignancies (chronic lymphocytic leukemia, B-cell lymphomas, acute promyelocytic leukemias, acute lymphocytic leukemia and CML). In CML, abnormal expression of several miRNAs has been described (miR-15a, miR-16, miR-142, miR-155, miR-181, miR-221, let7a and the polycistronic miR-17-92 cluster) [4–6] and we have currently demonstrated that down-regulation of miR-10a leads to an abnormal proliferation of CML cells through regulation of USF2 gene expression . A role for microRNA expression as a prognostic factor in various tumors has only been recently described,  while no information is available regarding their involvement in the response to chemotherapy. Recent studies suggest that miR-15b and miR-16, and miR-27a and miR-451 modulate multidrug resistance by targeting BCL2 and MDR1 respectively [8, 9].
With the objective of deciphering a potential miRNA expression signature associated with IM resistance, we analyzed the expression profile of 250 miRNAs by Q-RT-PCR using TaqMan methodology (PE Applied Biosystems, Foster City, CA) using bone marrow mononuclear cells from patients with Ph+ CML at diagnoses (n = 8). All patients were treated with identical doses of IM (400 mg daily) as first-line therapy. Three patients were considered to be primary resistant (less than partial cytogenetic response (Ph+ > 35%) after 12 months on IM; 400 mg/day for the first six months and 800 mg/day thereafter) while the other 5 patients showed a complete cytogenetic response at 12 months. In every case, we examined the sample at diagnosis and twelve months after treatment with IM for the presence of the clinically significance mutations T315I, Y253H, Y253F, E225K and E255V using allele-specific oligonucleotide polymerase chain reaction (ASO-PCR), and none of these mutations was detected (data not shown). All studies were approved by the Research Review Boards at the University of Navarra. Informed consent was obtained from all the patients.
RNA extraction of nucleated cells and reverse transcription were carried out as described . Briefly, total RNA was extracted with Ultraspec (Biotecx, Houston, TX, USA) following the manufacturer's instructions. 5 ng of total RNA was used to synthesize a specific cDNA of each analyzed miRNA using stem-loop miRNA-specific RT primer, according to the TaqMan MicroRNA Assay protocol (Applied Biosystems, Foster City, CA). Expression of 250 miRNAs was analyzed using specific primers and TaqMan probe for each miRNA according to the TaqMan MicroRNA Assay Protocol (Applied Biosystems, Foster City, CA). Q-RT-PCR was performed using an Applied Biosystems 7300 Sequence Detection system as described . Expression of miRNA was normalized using the expression of the housekeeping gene RNU6B. Expression of miRNAs in every patient is included in the Additional file 1. Relative quantification of expression of analyzed miRNAs was calculated with the 2-ΔΔCt method (Applied Biosystems. User Bulletin N°2 (P/N 4303859)). Data are presented as log 2-ΔΔCt of the relative quantity of miRNAs, normalized and compared with the expression in samples obtained from patients that responded to IM. A supervised analysis using the SAM algorithm (Significant Analysis of Microarrays) was performed in order to identify miRNAs with statistically significant changes in expression between both groups.
In order to determine potential genes and signaling pathways implicated in resistance to IM, we analyzed predicted targets of the 19 miRNAs differentially expressed using four different algorithms (mirBase, miRanda, TargetScan and PicTar). Because each of the four approaches generated an unpredictable number of false positives, results were intersected to identify the genes commonly predicted by at least three of the algorithms. Among all the possible targets for these miRNAs we found several membrane transporters that belong to the ATP binding cassette (ABC) superfamily of transmembrane transporters, which have been implicated in resistance to chemotherapy. These transporters are ABCC5, ABCA1 and ABCB6, potential targets of hsa-miR-199a, hsa-miR-183 and hsa-miR-29c respectively. Our own unpublished studies indicate that up-regulation of ABCA1 is observed in CML patients that develop resistance to IM (data not shown), suggesting that alterations of ABC transporters mediated by miRNAs might be a mechanism of resistance to IM. Other targets of the differentially expressed miRNAs such as RAB11A (possible target of hsa-miR-520a) or SIRT1 (possible target of hsa-miR-199a) have recently been implicated in resistance to IM [10, 11].
In conclusion, we identify a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML. Further studies are nevertheless required to validate the role of these miRNAs as predictors for resistance to IM and to identify miRNAs targets and their function in resistance to IM in CML.
Supported by grants from Beca Ortiz de Landázuri 2006, Departamento de Salud-Gobierno de Navarra; Fondo de Investigación Sanitaria (FIS, Spain), PI070602, PI070608, PI060003, CP07/00215 and RD06/0020; Junta de Andalucía 0386/2006 and 0004/2007; Asociación Medicina e Investigación (AMI) and "UTE project CIMA". We thank Dr. Victor Segura for helping us with the bioinformatic analysis (Unidad de Bioinformática. CIMA).
- Apperley JF: Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncology. 2007, 8: 1018-29. 10.1016/S1470-2045(07)70342-XView ArticlePubMedGoogle Scholar
- Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine. 2006, 355: 2408-17. 10.1056/NEJMoa062867View ArticlePubMedGoogle Scholar
- Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, Pérez-Roger I, García-Foncillas J, Torres A, Heiniger A, Calasanz MJ, Fortes P, Román-Gómez J, Prósper F: Hematopoietic tissue-specific hsa-miR-10a is down regulated in Chronic Myeloid Leukemia. Molecular Cancer Research. 2008, 6: 1830-40. 10.1158/1541-7786.MCR-08-0167View ArticlePubMedGoogle Scholar
- Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-8. 10.1038/nature03702View ArticlePubMedGoogle Scholar
- Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP, Sloand EM, Kajigaya S, Young NS: Hematopoietic-specific microRNA expression in human cells. Leukemia Research. 2006, 30: 643-647. 10.1016/j.leukres.2005.09.001View ArticlePubMedGoogle Scholar
- Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M: Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007, 109: 4399-405. 10.1182/blood-2006-09-045104View ArticlePubMedGoogle Scholar
- Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 2008, 26: 5078-87. 10.1200/JCO.2008.17.5554PubMed CentralView ArticlePubMedGoogle Scholar
- Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. International Journal of Cancer. 2008, 123: 372-9. 10.1002/ijc.23501. 10.1002/ijc.23501View ArticleGoogle Scholar
- Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008, 76: 582-8. 10.1016/j.bcp.2008.06.007PubMed CentralView ArticlePubMedGoogle Scholar
- Chung YJ, Kim TM, Kim DW, Namkoong H, Kim HK, Ha SA, Kim S, Shin SM, Kim JH, Lee YJ, Kang HM, Kim JW: Gene expression signatures associated with the resistance to imatinib. Leukemia. 2006, 20: 1542-50. 10.1038/sj.leu.2404310View ArticlePubMedGoogle Scholar
- Lee SM, Bae JH, Kim MJ, Lee HS, Lee MK, Chung BS, Kim DW, Kang CD, Kim SH: Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther. 2007, 322: 1084-92. 10.1124/jpet.107.124461View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.